Analyses of association between PPAR gamma and EPHX1 polymorphisms and susceptibility to COPD in a Hungarian cohort, a case-control study

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Penyige, Andras ^a   Poliska, Szilard ^a,b   Csanky, Eszter ^b,e   Scholtz, Beata ^b   Dezso, Balazs ^b   Schmelczer, Ivan ^a   Kilty, Iain ^c   Takacs, Laszlo ^d   Nagy, Laszlo ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d Biosystems International SAS   (France)

^e Semmelweis Health Care Center   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; EPOXIDE HYDROLASE; HISTIDINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; EPHX1 PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; EXON; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNGARY; LOGISTIC REGRESSION ANALYSIS; LUNG ALVEOLUS MACROPHAGE; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MICROSOME; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK FACTOR; SMOKING;

CASE-CONTROL STUDIES; EPOXIDE HYDROLASES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; HUNGARY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING;

EID: 77958601166     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-152     Document Type: Article

References (40)

1. Sandford AJ, Silverman EK. Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction. Thorax 2002, 57(8):736-741. 10.1136/thorax.57.8.736, 1746410, 12149538.
2. Seifart C, Plagens A. Genetics of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007, 2(4):541-550. 2699975, 18268927.
3. Joos L, Pare PD, Sandford AJ. Genetic risk factors of chronic obstructive pulmonary disease. Swiss Med Wkly 2002, 132(3-4):27-37.
4. Sandford AJ, Joos L, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Curr Opin Pulm Med 2002, 8(2):87-94. 10.1097/00063198-200203000-00002, 11845002.
5. Molfino NA. Genetics of COPD. Chest 2004, 125(5):1929-1940. 10.1378/chest.125.5.1929, 15136409.
6. Hersh CP, DeMeo DL, Silverman EK. National Emphysema Treatment Trial state of the art: genetics of emphysema. Proc Am Thorac Soc 2008, 5(4):486-493. 10.1513/pats.200706-078ET, 2645324, 18453360.
7. Hersh CP, Demeo DL, Lange C, Litonjua AA, Reilly JJ, Kwiatkowski D, Laird N, Sylvia JS, Sparrow D, Speizer FE. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol 2005, 33(1):71-78. 10.1165/rcmb.2005-0073OC, 2715305, 15817713.
8. Szatmari I, Nagy L. Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function. EMBO J 2008, 27(18):2353-2362. 10.1038/emboj.2008.160, 2525841, 18716631.
9. Asada K, Sasaki S, Suda T, Chida K, Nakamura H. Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 2004, 169(2):195-200. 10.1164/rccm.200207-740OC, 14563653.
10. Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006, 36(12):1494-1504. 10.1111/j.1365-2222.2006.02604.x, 17177672.
11. Oh SH, Park SM, Lee YH, Cha JY, Lee JY, Shin EK, Park JS, Park BL, Shin HD, Park CS. Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms with the development of asthma. Respir Med 2009, 103(7):1020-1024. 10.1016/j.rmed.2009.01.015, 19217272.
12. Standiford TJ, Keshamouni VG, Reddy RC. Peroxisome proliferator-activated receptor-{gamma} as a regulator of lung inflammation and repair. Proc Am Thorac Soc 2005, 2(3):226-231. 10.1513/pats.200501-010AC, 16222042.
13. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology 2006, 17(1):89-99. 10.1097/01.ede.0000187627.70026.23, 16357600.
14. Hersh CP, Demeo DL, Lazarus R, Celedon JC, Raby BA, Benditt JO, Criner G, Make B, Martinez FJ, Scanlon PD. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173(9):977-984. 10.1164/rccm.200509-1452OC, 2662917, 16456143.
15. Hersh CP, DeMeo DL, Reilly JJ, Silverman EK. Xenobiotic metabolizing enzyme gene polymorphisms predict response to lung volume reduction surgery. Respir Res 2007, 8:59. 10.1186/1465-9921-8-59, 2048957, 17686149.
16. Brogger J, Steen VM, Eiken HG, Gulsvik A, Bakke P. Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. Eur Respir J 2006, 27(4):682-688. 10.1183/09031936.06.00057005, 16585076.
17. Chappell S, Daly L, Morgan K, Guetta-Baranes T, Roca J, Rabinovich R, Lotya J, Millar AB, Donnelly SC, Keatings V. Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD. Eur Respir J 2008, 32(4):931-937. 10.1183/09031936.00065308, 18614560.
18. Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 2000, 117(2 Suppl):1S-4S. 10.1378/chest.117.2_suppl.1S, 10673465.
19. Szatmari I, Gogolak P, Im JS, Dezso B, Rajnavolgyi E, Nagy L. Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity 2004, 21(1):95-106. 10.1016/j.immuni.2004.06.003, 15345223.
20. Tsakiris I, Soos G, Nemes Z, Kiss SS, Andras C, Szanto J, Dezso B. The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas: the coexistence predicts a poor prognosis regardless of EGFR levels. J Cancer Res Clin Oncol 2008, 134(4):439-451. 10.1007/s00432-007-0304-z, 17922141.
21. Gogolak P, Rethi B, Szatmari I, Lanyi A, Dezso B, Nagy L, Rajnavolgyi E. Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma. Blood 2007, 109(2):643-652. 10.1182/blood-2006-04-016840, 16968896.
22. Chiano MN, Clayton DG. Genotypic relative risks under ordered restriction. Genet Epidemiol 1998, 15(2):135-146. 10.1002/(SICI)1098-2272(1998)15:2<135::AID-GEPI3>3.0.CO;2-5, 9554552.
23. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005, 15(2):97-98. 10.1038/sj.cr.7290272, 15740637.
24. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis http://analysis.bio-x.cn. Cell Res 2009, 19(4):519-523. 10.1038/cr.2009.33, 19290020.
25. Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997, 350(9078):630-633. 10.1016/S0140-6736(96)08061-0, 9288046.
26. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res 1998, 58(23):5291-5293.
27. Huang TH, Razmovski-Naumovski V, Kota BP, Lin DS, Roufogalis BD. The pathophysiological function of peroxisome proliferator-activated receptor-gamma in lung-related diseases. Respir Res 2005, 6:102. 10.1186/1465-9921-6-102, 1242255, 16153299.
28. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006, 533(1-3):101-109. 10.1016/j.ejphar.2005.12.048, 16458290.
29. Omiecinski CJ, Hassett C, Hosagrahara V. Epoxide hydrolase--polymorphism and role in toxicology. Toxicol Lett 2000, 112-113:365-370. 10.1016/S0378-4274(99)00235-0, 10720753.
30. Caito S, Yang SR, Kode A, Edirisinghe I, Rajendrasozhan S, Phipps RP, Rahman I. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, PPARgamma agonists, differentially regulate cigarette smoke-mediated pro-inflammatory cytokine release in monocytes/macrophages. Antioxid Redox Signal 2008, 10(2):253-260. 10.1089/ars.2007.1889, 17970647.
31. Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol 2003, 170(5):2663-2669.
32. Reddy RC. Immunomodulatory role of PPAR-gamma in alveolar macrophages. J Investig Med 2008, 56(2):522-527.
33. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998, 339(14):953-959. 10.1056/NEJM199810013391403, 9753710.
34. Capon F, Allen MH, Ameen M, Burden AD, Tillman D, Barker JN, Trembath RC. A synonymous SNP of the corneodesmosin gene leads to increased mRNA stability and demonstrates association with psoriasis across diverse ethnic groups. Hum Mol Genet 2004, 13(20):2361-2368. 10.1093/hmg/ddh273, 15333584.
35. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007, 67(20):9609-9612. 10.1158/0008-5472.CAN-07-2377, 17942888.
36. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20(3):284-287. 10.1038/3099, 9806549.
37. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000, 26(1):76-80. 10.1038/79216, 10973253.
38. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003, 63(13):3560-3566.
39. Jiang J, Gajalakshmi V, Wang J, Kuriki K, Suzuki S, Nakamura S, Akasaka S, Ishikawa H, Tokudome S. Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population. Cancer Sci 2005, 96(8):507-512. 10.1111/j.1349-7006.2005.00072.x, 16108832.
40. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005, 26(2):449-457. 10.1093/carcin/bgh336, 15550453.